Company
Headquarters: Hulin, China
Employees: 3,321
CN¥8.62 Billion
CNY as of Jan. 1, 2026
US$1.23 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥1.59 B |
| EBITDA | CN¥1.01 B |
| Gross Profit TTM | CN¥621.4 M |
| Profit Margin | -20.85% |
| Operating Margin | -68.36% |
| Quarterly Revenue Growth | -44.10% |
Heilongjiang ZBD Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603567 wb_incandescent